Panadol Osteo Paracetamol 665 mg modified release tablet

Brand Origin and Manufacturing

Panadol Osteo is a brand of paracetamol (acetaminophen) tablets formulated for the relief of persistent pain associated with osteoarthritis and muscle aches. The brand originated in the United Kingdom and was initially developed by GlaxoSmithKline (GSK), a major pharmaceutical company. In 2022, GSK spun off its consumer healthcare division, including the Panadol brand, into a new company named Haleon. This move allowed Haleon to focus exclusively on over-the-counter health products, while GSK continued its focus on prescription medicines and vaccines.

The manufacturing of Panadol Osteo tablets occurs in multiple countries, ensuring a global supply to meet the demand in various markets. The tablets are typically white to off-white, film-coated, capsule-shaped, and embossed with the logo “8” on the front face and plain on the back face. They are designed for sustained release, providing effective relief from persistent pain for up to 8 hours.

Ownership Structure

As of 2026, Haleon is the ultimate owner of the Panadol Osteo brand. Haleon is headquartered in the United Kingdom and operates globally, offering a wide range of consumer healthcare products. The company is publicly traded and has a diverse shareholder base, including institutional and individual investors. There are no known subsidiaries that own the Panadol Osteo brand locally; it is managed directly by Haleon in all markets where it is sold.